AR086196A1 - Derivados de pirazolo[3,4-c]quinolina, inhibidores de quinasa - Google Patents

Derivados de pirazolo[3,4-c]quinolina, inhibidores de quinasa

Info

Publication number
AR086196A1
AR086196A1 ARP120101360A AR086196A1 AR 086196 A1 AR086196 A1 AR 086196A1 AR P120101360 A ARP120101360 A AR P120101360A AR 086196 A1 AR086196 A1 AR 086196A1
Authority
AR
Argentina
Prior art keywords
diseases
alkylcycloalkyl
heterocycloalkyl
aralkyl
heteroaryl
Prior art date
Application number
Other languages
English (en)
Inventor
Michael Thormann
Andreas Treml
Michael Almstetter
Roland Koestler
Nasser Yehia
Original Assignee
Origenis Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Origenis Gmbh filed Critical Origenis Gmbh
Publication of AR086196A1 publication Critical patent/AR086196A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

Compuestos de fórmula (1) capaces de inhibir una o más quinasas, especialmente SYK (tirosina quinasa esplénica), LRRK2 (quinasa con repeticiones ricas en leucina 2) y/o MYLK (quinasa de cadena ligera de miosina) o mutantes de estas. Los compuestos encuentran aplicación en el tratamiento de una variedad de enfermedades. Estas enfermedades incluyen enfermedades autoinmunes, enfermedades inflamatorias, enfermedades óseas, metabólicas, neurológicas y neurodegenerativas, cáncer, enfermedades cardiovasculares, alergias, asma, enfermedad de Alzheimer, enfermedad de Parkinson, trastornos de la piel, enfermedades del ojo, enfermedades infecciosas y enfermedades hormonales.Reivindicación 1: Un compuesto de fórmula (1) donde A es NH, O, S, C=O, NR3 o CR4R5; Cy es un grupo arilo, heteroarilo, cicloalquilo, heterocicloalquilo, alquilcicloalquilo, heteroalquilcicloalquilo, aralquilo o heteroaralquilo opcionalmente sustituido; R1 es un grupo alquilo, alquenilo, alquinilo, heteroalquilo, arilo, heteroarilo, cicloalquilo, alquilcicloalquilo, heteroalquilcicloalquilo, heterocicloalquilo, aralquilo o heteroaralquilo opcionalmente sustituido; R2 es un átomo de hidrógeno, un átomo de halógeno, NO2, N3, OH, SH, NH2 o un grupo alquilo, alquenilo, alquinilo, heteroalquilo, arilo, heteroarilo, cicloalquilo, alquilcicloalquilo, heteroalquilcicloalquilo, heterocicloalquilo, aralquilo o heteroaralquilo; R3 es un grupo alquilo, alquenilo, alquinilo, heteroalquilo, arilo, heteroarilo, cicloalquilo, alquilcicloalquilo, heteroalquilcicloalquilo, heterocicloalquilo, aralquilo o heteroaralquilo; R4 es un átomo de hidrógeno NO3, N3, OH, SH, NH2 o un grupo alquilo, alquenilo, alquinilo, heteroalquilo, arilo, heteroarilo, cicloalquilo, alquilcicloalquilo, heteroalquilcicloalquilo, heterocicloalquilo, aralquilo o heteroaralquilo; y R5 es un átomo de hidrógeno NO3, N3, OH, SH, NH2 o un grupo alquilo, alquenilo, alquinilo, heteroalquilo, arilo, heteroarilo, cicloalquilo, alquilcicloalquilo, heteroalquilcicloalquilo, heterocicloalquilo, aralquilo o heteroaralquilo; o una sal, un éster, un solvato o un hidrato farmacéuticamente aceptables del mismo o una formulación farmacéuticamente aceptable del mismo.
ARP120101360 2011-04-21 2012-04-20 Derivados de pirazolo[3,4-c]quinolina, inhibidores de quinasa AR086196A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11003373 2011-04-21

Publications (1)

Publication Number Publication Date
AR086196A1 true AR086196A1 (es) 2013-11-27

Family

ID=44501589

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120101360 AR086196A1 (es) 2011-04-21 2012-04-20 Derivados de pirazolo[3,4-c]quinolina, inhibidores de quinasa

Country Status (2)

Country Link
AR (1) AR086196A1 (es)
UY (1) UY34032A (es)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10407446B2 (en) 2016-12-20 2019-09-10 Astrazeneca Ab Amino-triazolopyridine compounds and their use in treating cancer
JP2020517711A (ja) * 2017-04-27 2020-06-18 バーディー バイオファーマシューティカルズ インコーポレイテッド ２−アミノ−キノリン誘導体
US11517567B2 (en) 2017-06-23 2022-12-06 Birdie Biopharmaceuticals, Inc. Pharmaceutical compositions
US11633495B2 (en) 2014-01-10 2023-04-25 Birdie Biopharmaceuticals, Inc. Compounds and compositions for immunotherapy
US11702476B2 (en) 2016-01-07 2023-07-18 Birdie Biopharmaceuticals, Inc. Anti-EGFR combinations for treating tumors

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11633495B2 (en) 2014-01-10 2023-04-25 Birdie Biopharmaceuticals, Inc. Compounds and compositions for immunotherapy
US11633494B2 (en) 2014-01-10 2023-04-25 Birdie Biopharmaceuticals, Inc. Compounds and compositions for immunotherapy
US11786604B2 (en) 2014-01-10 2023-10-17 Birdie Biopharmaceuticals, Inc. Compounds and compositions for treating HER2 positive tumors
US11702476B2 (en) 2016-01-07 2023-07-18 Birdie Biopharmaceuticals, Inc. Anti-EGFR combinations for treating tumors
US10407446B2 (en) 2016-12-20 2019-09-10 Astrazeneca Ab Amino-triazolopyridine compounds and their use in treating cancer
US11136340B2 (en) 2016-12-20 2021-10-05 Astrazeneca Ab Amino-triazolopyridine compounds and their use in treating cancer
US11746118B2 (en) 2016-12-20 2023-09-05 Astrazeneca Ab Amino-triazolopyridine compounds and their use in treating cancer
JP2020517711A (ja) * 2017-04-27 2020-06-18 バーディー バイオファーマシューティカルズ インコーポレイテッド ２−アミノ−キノリン誘導体
US11834448B2 (en) 2017-04-27 2023-12-05 Birdie Biopharmaceuticals, Inc. 2-amino-quinoline derivatives
US11517567B2 (en) 2017-06-23 2022-12-06 Birdie Biopharmaceuticals, Inc. Pharmaceutical compositions

Also Published As

Publication number Publication date
UY34032A (es) 2012-11-30

Similar Documents

Publication Publication Date Title
EA201301183A1 (ru) Гетероциклические соединения в качестве ингибиторов киназ
EA201301184A1 (ru) Пиразоло[4,3-d]пиримидины, пригодные в качестве ингибиторов киназ
EA201500182A1 (ru) 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ
PH12016500359A1 (en) Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
MX2012007273A (es) Pteridinonas como inhibidores de la quinasa tipo polo.
EA201591753A1 (ru) 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh
UA109698C2 (xx) Похідні азаіндазолу або діазаіндазолу як медикамент
MD4575C1 (ro) Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin
BR112015028501B8 (pt) Compostos derivados de bipirazol, seus sais, composição compreendendo o composto ou o sal, método de inibição in vitro de uma atividade de jak1, e processo de preparação de sal de ácido fosfórico
EA201290807A1 (ru) Циклобутановые и метилциклобутановые производные в качестве ингибиторов янус-киназы
GEP201706608B (en) 1 - arylcarbonyl - 4 - oxy – piperidine compounds useful for the treatment of neurodegenerative diseases
EA201390579A1 (ru) Производные хиназолин-4(3h)-она, используемые как ингибиторы pi3-киназы
EA201200318A1 (ru) Гетероциклические оксимы
AR086196A1 (es) Derivados de pirazolo[3,4-c]quinolina, inhibidores de quinasa
MX2013008296A (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
EA201490272A1 (ru) Новые 4-пиперидинильные соединения для применения в качестве ингибиторов танкиразы
MX2012004089A (es) Inhibidores de hsp90.
NZ599356A (en) Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
JO3279B1 (ar) مشتقات 2-((4- امينو -3- (3- فلورو-5- هيدروكسي فينيل)-h1- بيرازولو [d-3,4] بيرمدين-1-يل )ميثيل )- 3- (2- تراي فلورو ميثيل ) بينزيل ) كوينازولين -4 (h3)- واحد واستخدامها كمثبطات فوسفواينوسيتايد 3- كاينيز
IN2014DN07885A (es)
RU2012125971A (ru) Новые химические соединения производные 2,4-диамино-1,3,5-триазина для профилактики и лечения заболеваний человека и животных
PH12016501977A1 (en) 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
SA519401322B1 (ar) مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2
EA201791367A1 (ru) Соединения 2,3,4,5-тетрагидропиридин-6-амин и 3,4-дигидро-2h-пиррол-5-амин - ингибиторы бета-секретазы
GB201302704D0 (en) Therapeutic compounds

Legal Events

Date Code Title Description
FC Refusal